Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - PA: CHVI Vaccine Discovery and Social Research

University of Toronto

$225,640.00

Application of novel assays to quantify mucosal susceptibility to HIV and to define key mucosal targets during HIV transmission.

EF 2012-13

Résumé
There is great variability in susceptibility from one person to another, and less than one in a hundred sexual exposures to HIV results in infection. In addition, some recent trial of methods to prevent HIV - including vaccines and microbicides - have actually increased HIV acquisition among trial participants for reasons that we do not fully understand. While we know that immune differences in the genital lining are an important determinant of whether a person is infected after a sexual HIV exposure, we don't know enough about these differences to be able to accurately assess a person's HIV risk. Therefore, the development of safe and non-invasive laboratory tests to estimate a person's susceptibility in the genital tract would be useful in clinical studies of new HIV prevention tools. We have developed a tool that we hope will be useful for this purpose,that only requires the collection of a genital sample similar to that used for a PAP test, and that can be run in a few hours. We aim to demonstrate that this new assay works, and to use the test to assess whether certain types of cell in the genital lining are preferred "targets" for HIV during sexual transmission. If so, then a microbicide or vaccine that specifically protects these cells could be a useful way to prevent HIV transmission.
Programme
Operating Grant - PA: CHVI Vaccine Discovery and Social Research
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
286280
Name
Kaul Rupert
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
Application of novel assays to quantify mucosal susceptibility to HIV and to define key mucosal targets during HIV transmission.
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$225,640
Cihrequipment2
$0
Programname2
Operating Grant - PA: CHVI Vaccine Discovery and Social Research
Keyworddelim
Ectocervical Biopsy; Endocervical Cytobrush Sample; Female Genital Tract; Genital Explants; Hiv Pseudovirus; Hiv Susceptibility; Kenya
Abstract
There is great variability in susceptibility from one person to another, and less than one in a hundred sexual exposures to HIV results in infection. In addition, some recent trial of methods to prevent HIV - including vaccines and microbicides - have actually increased HIV acquisition among trial participants for reasons that we do not fully understand. While we know that immune differences in the genital lining are an important determinant of whether a person is infected after a sexual HIV exposure, we don't know enough about these differences to be able to accurately assess a person's HIV risk. Therefore, the development of safe and non-invasive laboratory tests to estimate a person's susceptibility in the genital tract would be useful in clinical studies of new HIV prevention tools. We have developed a tool that we hope will be useful for this purpose,that only requires the collection of a genital sample similar to that used for a PAP test, and that can be run in a few hours. We aim to demonstrate that this new assay works, and to use the test to assess whether certain types of cell in the genital lining are preferred "targets" for HIV during sexual transmission. If so, then a microbicide or vaccine that specifically protects these cells could be a useful way to prevent HIV transmission.
Competitiondate
201303
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kaul, Rupert
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $225,640~ $0~